AI Article Synopsis
- Researchers developed multifunctional liposomes (ITLPs) that carry imatinib inside and have TRAIL on their surface to target TRAIL-resistant tumor cells.
- The ITLPs showed a significant increase in cancer cell death (50% more) compared to standard treatments, activating the apoptosis pathway to kill HT-29 cells.
- In animal studies, ITLPs effectively suppressed tumors by 61.8% with minimal side effects, suggesting they could be a promising therapy for resistant tumors.
Article Abstract
To solve the problem of resistance of tumor cells to TRAIL and the inevitable side effects of imatinib during treatment, we successfully prepared a kind of multifunctional liposome that encapsulated imatinib in its internal water phase and inserted TRAIL on its membrane in this study, which named ITLPs. The liposomes appeared uniform spherical and the particle size was approximately 150 nm. ITLPs showed high accumulation in TRAIL-resistance cells and HT-29 tumor-bearing mice model. In vitro cytotoxicity assay results showed that the killing activity of HT-29 cells treated with ITLPs increased by 50% and confirmed that this killing activity was mediated by the apoptosis pathway. Through mechanism studies, it was found that ITLPs arrested up to 32.3% of cells in phase M to exert anti-tumor effects. In vivo anti-tumor study showed that ITLPs achieved 61.8% tumor suppression and little toxicity in the HT-29 tumor-bearing mice model. Overall results demonstrated that codelivery of imatinib and TRAIL via liposomes may be a prospective method in the treatment of the TRAIL-resistance tumor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10837450.2024.2301763 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulation of NLRP3 inflammasome and Caspase-3/4/11 by 2',4'-dihydroxychalcone contributes to anti-colorectal cancer.
Phytomedicine
December 2024
Macau Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999078, China; College of Pharmacy, Guangxi Medical University, Nanning 530021, China. Electronic address:
Background: Chronic inflammation is closely related to the occurrence and progression of many cancers, especially colorectal cancer (CRC), which can be triggered by repeated and sustained induction of colitis in mice. CRC is a typical type of cancer that can be caused by inflammation and NLRP3 inflammasome dysregulation plays a certain role in the pathogenesis of CRC.
Purpose: As an edible Chinese medicine, Abrus cantoniensis Hance (ACH) has both anti-inflammatory and anti-tumor activities.
Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.
PLoS One
April 2024
Biotechnology Discovery Research, Lilly Technology Center North, Indianapolis, IN, United States of America.
Many oncology antibody-drug conjugates (ADCs) have failed to demonstrate efficacy in clinic because of dose-limiting toxicity caused by uptake into healthy tissues. We developed an approach that harnesses ADC affinity to broaden the therapeutic index (TI) using two anti-mesenchymal-epithelial transition factor (MET) monoclonal antibodies (mAbs) with high affinity (HAV) or low affinity (LAV) conjugated to monomethyl auristatin E (MMAE). The estimated TI for LAV-ADC was at least 3 times greater than the HAV-ADC.
View Article and Find Full Text PDFPITPNC1 Suppress CD8 T cell immune function and promote radioresistance in rectal cancer by modulating FASN/CD155.
J Transl Med
January 2024
Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Background: Radioresistance is a primary factor contributing to the failure of rectal cancer treatment. Immune suppression plays a significant role in the development of radioresistance. We have investigated the potential role of phosphatidylinositol transfer protein cytoplasmic 1 (PITPNC1) in regulating immune suppression associated with radioresistance.
View Article and Find Full Text PDFEfficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes.
Pharm Dev Technol
January 2024
Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China.
Article Synopsis
- Researchers developed multifunctional liposomes (ITLPs) that carry imatinib inside and have TRAIL on their surface to target TRAIL-resistant tumor cells.
- The ITLPs showed a significant increase in cancer cell death (50% more) compared to standard treatments, activating the apoptosis pathway to kill HT-29 cells.
- In animal studies, ITLPs effectively suppressed tumors by 61.8% with minimal side effects, suggesting they could be a promising therapy for resistant tumors.
[Manganese-based nanoparticles for chemodynamic therapy of gastrointestinal cancer].
Nan Fang Yi Ke Da Xue Xue Bao
August 2023
Department of Spleen and Stomach Diseases, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510515, China.
Objective: To investigate the physicochemical features of glucose oxidase-loaded and manganese-based mesoporous silica nanoparticles (MSN@Mn-GOx) and its antitumor effect against gastrointestinal cancer.
Methods: The morphology, particle size and Fenton-like properties of MSN@Mn-GOx nanoparticles were analyzed using transmission electron microscopy (TEM), dynamic light scattering (DLS), Zeta potential analysis, ultraviolet absorption spectroscopy, energy dispersive spectroscopy and X-ray photoelectron spectroscopy. A mouse model bearing human colon cancer HT-29 xenograft was established to examine the antitumor effect of MSN@Mn-GOx using MRI imaging.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!